Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: J Invest Dermatol. 2020 Jul 30;141(3):575–585. doi: 10.1016/j.jid.2020.07.011

Figure 2:

Figure 2:

Jak1/3 inhibition with tofacitinib suppresses IL-15-induced granzyme B production by CD8 T cells. (a-d) Splenocytes from naive mice were stimulated for 30 or 72 hours with tofacitinib or vehicle in the presence of various cytokines. Cells were stimulated with PMA and ionomycin in the presence of brefeldin A for the last 4 hours and analyzed by flow cytometry for the expression of intracellular granzyme B and IFN-γ. Data are representative of at least 3 individual experiments performed with duplicates. Gating strategy: live, singlets, CD3, CD44high, CD8β or CD4. (e and f) Splenocytes from L. major-infected mice were stimulated with tofacitinib or vehicle in the presence or leishmania antigen. Supernatants were collected at 24h post-antigen stimulation and used to perform ELISA for (e) GzmB and (f) IFN-γ. Bar graphs are representative of 2 individual experiments with 5 mice per group with similar results.